Navigation Links
12-Month ATLANTA Trial Data Show Sustained Benefit of Catania(TM) Stent in Treatment of De Novo Coronary Lesions
Date:10/13/2008

inflammatory, bacterial-resistant, and essentially cloaks the device's presence from the body to promote healthy endothelial cell growth without stimulating platelet activation.

"We found the CATANIA(TM) stent to be highly deliverable, trackable, and flexible in even the most tortuous anatomy," said Dr. Tamburino. "The Polyzene(R)-F surface treatment endows the stent with exceptional qualities that not only create a highly lubricious system that inspires user confidence and improved pushability, but also hides the stent from the body's defenses, which reduces platelet aggregation and the potential for thrombosis."

ABOUT NANOTHIN POLYZENE(R)-F

The proprietary NanoThin Polyzene(R)-F polymer can be applied to or mixed with other substances to allow for a diverse range of bioscience and industrial applications on a multitude of substrates, including other polymers, metals, and ceramics. Medical devices coated with Polyzene(R)-F do not cause a negative reaction in the body when introduced, eliciting a normalized and positive bodily response. Polyzene(R)-F can be customized for the desired application and applied in a variety of ways including as a coating, extrusion, weaving, or electro-spinning ranging in thickness from less than 40 nanometers to more than 200 nanometers. The base substrate will be endowed with the properties of the polymer.

About CeloNova BioSciences, Inc.

Headquartered in Newnan, Georgia, CeloNova BioSciences, Inc., is a developer of novel medical devices that are enhanced by one of the Company's proprietary materials, Polyzene(R)-F. Polyzene(R)-F is highly lubricious, anti-thrombotic, anti-inflammatory, and bacterial-resistant making it an ideal surface treatment for implanted medical devices. The Company's current products include Embozene(TM) Color-Advanced Microspheres and the CATANIA(TM) Coronary Stent System with NanoThin Polyzene(R)-F. Neither product is currently approved for use in the United States. Other i
'/>"/>

SOURCE CeloNova BioSciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Long-Term 12-Month Safety Data Presented on ADHD Patch DAYTRANA(TM) (methylphenidate transdermal system)
2. Neurobiological Technologies Announces FDA Agreement to Consolidate Viprinex Phase 3 Trials Accelerating Time to Pivotal Data
3. XTENT Announces Clinical Trial Data to be Presented at Annual Meeting of Transcatheter Cardiovascular Therapeutics Next Week
4. Boston Scientific to Release Broad Range of Clinical Trial Data on the Performance of TAXUS(R) Coronary Stent Systems at TCT 2008
5. SCOLR Pharma Announces Completion of Patient Enrollment and Dosing for Pivotal Clinical Trial Evaluating Extended Release Ibuprofen
6. Boston Scientific Completes Clinical Trial Enrollment for Third-Generation Drug-Eluting Stent
7. Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months
8. Texas Cardiac Arrhythmia Institute at St. Davids Medical Center Selected to Conduct Clinical Trial for Device to Treat Atrial Fibrillation
9. Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD
10. Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Its Second Bavituximab Phase II Breast Cancer Trial
11. Dendreon Announces Interim Data From Phase 3 PROVENGE IMPACT Trial

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/10/2009)... 10 /PRNewswire/ -- JumpStart Inc., the Northeas...erates the progress of high growth early-stage bus... commitment of $250,000 in Checkpoint Surgical, LL...H medical device company is developing and commerc...ulator. ,, (Logo: http://www.newscom.com/cgi...
(Date:11/10/2009).... and TOKYO, Nov. 10 Ironwood Phar...nnounced that they have entered into an agreement ... commercialize the investigational compound linacl... Taiwan, and Thailand. Linaclotide is currently in... for the treatment of irritable bowel syndrome wit...
(Date:11/9/2009)...if., Nov. 9 Thoratec Cor...e-based mechanical circulatory support therapies t...oday that it will be participating in the Third An...y, November 10. ,, The presentation by Gary F. ...ll begin at 8 a.m., Pacific Standard Time (11 a.m....
Breaking Medicine Technology:JumpStart Invests in Checkpoint Surgical 2JumpStart Invests in Checkpoint Surgical 3Ironwood and Astellas Announce Japan Licensing Agreement for Linaclotide 2Ironwood and Astellas Announce Japan Licensing Agreement for Linaclotide 3Fewer Genital Warts Thanks to HPV Vaccine Program 59521 1Fewer Genital Warts Thanks to HPV Vaccine Program 59521 2Local farmers in Africa to benefit from school meal programs 59518 1Local farmers in Africa to benefit from school meal programs 59518 2Local farmers in Africa to benefit from school meal programs 59518 3ASTRO Gildas Club Chicago join to promote cancer survivorship 59515 1
...hrax(TM) shows lifesaving potential -, - HGS on ...l Stockpile beginning in ...ences, Inc. (Nasdaq: HGSI ) today announced that ... life-saving potential of its human,monoclonal ant...show that a,single dose of ABthrax, administered w...
...Anthera Pharmaceuticals,Inc., a privately held bio...y drugs, announced today that the U.S. Food and Dr...evelopment has granted A-001,orphan drug status fo...ts,with sickle cell disease., A-001 is currently ...e,II clinical trial in the United States called IM...
Other Medicine Technology:New Approach to Treating Anthrax Significantly Improves Survival Rates in Pivotal Efficacy Studies 2New Approach to Treating Anthrax Significantly Improves Survival Rates in Pivotal Efficacy Studies 3New Approach to Treating Anthrax Significantly Improves Survival Rates in Pivotal Efficacy Studies 4New Approach to Treating Anthrax Significantly Improves Survival Rates in Pivotal Efficacy Studies 5New Approach to Treating Anthrax Significantly Improves Survival Rates in Pivotal Efficacy Studies 6New Approach to Treating Anthrax Significantly Improves Survival Rates in Pivotal Efficacy Studies 7Anthera's A-001 Receives Orphan Drug Status for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease 2Anthera's A-001 Receives Orphan Drug Status for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease 3
(Date:11/9/2009)...th Highlighted During Broadcast ,, WASHINGTON,...iance (LCA) announced that LCA staff, advocates an...ork Stock Exchange(TM) (NYSE) tomorrow afternoon a.../cgi-bin/prnh/20081016/LCALOGO ) ,, Five and a...e, Richard Heimler will mark the end of the day,s ...
(Date:11/9/2009)...wire/ -- The Churchill Centre today announced th...J.W. "Bill" Marriott for his lifelong commitment t...ket practices and fostering an open and transparen...ve his award at a ceremony and dinner on Tuesday, ...tel. ,, "This is a testament to how Bill Marri...
(Date:11/9/2009)...st equally, study finds, , , MONDAY, No...olving drug Plavix (clopidogrel) works about the s...cal trials has found. , "After this study, I ca... women with this very important drug," said Dr. Je...osis at New York University Langone Medical Center...
(Date:11/9/2009)...ences in mood despite similar weight loss , ...gh-fat, low-carbohydrate diet such as the popular ...r to help people lose pounds over the course of a ...s will result in long-term improvement in mood, ac...s of Internal Medicine . , People on both diets...
(Date:11/9/2009)...ow may be too late when it comes to preventing or ...Club, Inc. (Take Off Pounds Sensibly), the nonprof... (Vocus) November 9, 2009 -- Tomorrow...proving a diabetes condition, according to TOPS Cl... weight-loss support organization., , ,Diabetes is...
Breaking Medicine News(10 mins):Health News:Lung Cancer Alliance Staff and Advocates to Ring Closing Bell of New York Stock Exchange(TM) 2Health News:J.W. 'Bill' Marriott to Receive Churchill Centre Award For Leadership 2Health News:No Gender Gap Found for Clot-Busting Drug 2Health News:No Gender Gap Found for Clot-Busting Drug 3Health News:To Feel Better, Low-Fat Diet May Be Best 2Health News:To Feel Better, Low-Fat Diet May Be Best 3Health News:Diabetes Prevention Is the Best Remedy, TOPS Medical Expert Says 2Health News:Diabetes Prevention Is the Best Remedy, TOPS Medical Expert Says 3
...ticals Corp. (OTC Bulletin Board: RPTP), today ann...rate overview and clinical pipeline,updates at two...The 7th Annual BIO Investor Forum, to be held Octo...m PT) in Telegraph Hill. A live audio webcast...
...WLP ) announced,that Angela Braly, president and C... in Norfolk, Va. this evening. Ms. Braly focused o...em need to come together to improve,both access to...s to "fix what is broken, without breaking what,wo...
...Advance in AF-Ablation,Technology, CARLSBAD, Cali...day that two important abstracts which evaluated i...ation system were presented at the 5th,Annual Hear... as Dr. Simon James and Dr. John Bourke of the,Fre...
... The University,of Minnesota, Twin Cities shattere... given in a single day today (Tuesday, Oct. 28) by...y reports. The official number will,be released on...d was set in,November of 2006 in Sanford, Florida....
...r foreign markets and plans,Canadian rollout, LOS...n Board: UKMA), a lifestyle multimedia and consume... personal development, announced today that,its ex...r,s Association (ERA) Conference in Las Vegas duri...
...ty Determinations, WASHINGTON, Oct. 28 National ...cial Security Administration,s,new "Compassionate ... which,will accelerate the processing of disabilit...llaboration with professional,case managers and st...
Other Medicine News:Health News:Raptor Pharmaceuticals Corp. to Present at Two Upcoming Healthcare Conferences 2Health News:Raptor Pharmaceuticals Corp. to Present at Two Upcoming Healthcare Conferences 3Health News:Raptor Pharmaceuticals Corp. to Present at Two Upcoming Healthcare Conferences 4Health News:WellPoint President and CEO Angela Braly Appears at the Norfolk Forum 2Health News:Innovative Atrial Fibrillation (AF) Catheter Ablation System From Ablation Frontiers is Subject of Two Abstracts at Heart Rhythm Congress UK 2Health News:Innovative Atrial Fibrillation (AF) Catheter Ablation System From Ablation Frontiers is Subject of Two Abstracts at Heart Rhythm Congress UK 3Health News:Innovative Atrial Fibrillation (AF) Catheter Ablation System From Ablation Frontiers is Subject of Two Abstracts at Heart Rhythm Congress UK 4Health News:University Of Minnesota Gives 11,538 Flu Shots Tuesday, Shattering Guinness World Record for Most Flu Shots in a Single Day 2Health News:uKarma Reports Progress With International Distribution Agreement for Its Xflowsion DVD Series 2Health News:National Patient Advocate Foundation (NPAF) Commends SSA's New 'Compassionate Allowances Process' 2
... a national reference laboratory and a worldwide l...pment. ARUP offers an extensive test menu of highl... anatomic pathology. Owned by the University of Ut...alf of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide l...pment. ARUP offers an extensive test menu of highl... anatomic pathology. Owned by the University of Ut...alf of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide l...pment. ARUP offers an extensive test menu of highl... anatomic pathology. Owned by the University of Ut...alf of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide l...pment. ARUP offers an extensive test menu of highl... anatomic pathology. Owned by the University of Ut...alf of the nation's university teaching hospitals ...
Medicine Products: